Eric Southam

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi request reprint Effect of the selective dopamine D3 receptor antagonist SB-277011-A on regional c-Fos-like expression in rat forebrain
    Eric Southam
    Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park North, Harlow, Essex, CM19 5AW, UK
    Brain Res 1149:50-7. 2007
  2. doi request reprint Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040
    Eric Southam
    GlaxoSmithKline, New Frontiers Science Park North, Third Avenue, Harlow, Essex, CM195AW, UK
    Psychopharmacology (Berl) 201:483-94. 2009
  3. ncbi request reprint Effect of lamotrigine on the activities of monoamine oxidases A and B in vitro and on monoamine disposition in vivo
    Eric Southam
    Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park North, Harlow, Essex, CM19 5AW, UK
    Eur J Pharmacol 519:237-45. 2005
  4. doi request reprint In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics
    Lee A Dawson
    Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Harlow, Essex, UK
    Eur J Pharmacol 627:106-14. 2010
  5. ncbi request reprint GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models
    Andrew D Medhurst
    Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline, Third Ave, Harlow, Essex, CM19 5AW, UK
    J Pharmacol Exp Ther 321:1032-45. 2007
  6. ncbi request reprint Reversal of isolation-rearing-induced PPI deficits by an alpha7 nicotinic receptor agonist
    Jackie Cilia
    Psychiatry CEDD, GlaxoSmithKline, Third Avenue, Harlow, CM19 5AW, UK
    Psychopharmacology (Berl) 182:214-9. 2005
  7. ncbi request reprint Anticonvulsant mechanisms for today and tomorrow
    Eric Southam
    Psychiatry CEDD, GlaxoSmithKline, Harlow, Essex, UK
    Drug News Perspect 18:483-7. 2005
  8. ncbi request reprint In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia
    Lee A Dawson
    Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline, Essex, UK
    Neuropsychopharmacology 33:1642-52. 2008
  9. ncbi request reprint Broad spectrum anticonvulsant activity of BW534U87: possible role of an adenosine-dependent mechanism
    Eric Southam
    GlaxoSmithKline, New Frontiers Science Park, Essex CM195AW, Harlow, UK
    Pharmacol Biochem Behav 74:111-8. 2002
  10. doi request reprint Chandelier cartridges in the prefrontal cortex are reduced in isolation reared rats
    Claire Bloomfield
    Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK
    Synapse 62:628-31. 2008

Detail Information

Publications10

  1. ncbi request reprint Effect of the selective dopamine D3 receptor antagonist SB-277011-A on regional c-Fos-like expression in rat forebrain
    Eric Southam
    Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park North, Harlow, Essex, CM19 5AW, UK
    Brain Res 1149:50-7. 2007
    ....
  2. doi request reprint Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040
    Eric Southam
    GlaxoSmithKline, New Frontiers Science Park North, Third Avenue, Harlow, Essex, CM195AW, UK
    Psychopharmacology (Berl) 201:483-94. 2009
    ....
  3. ncbi request reprint Effect of lamotrigine on the activities of monoamine oxidases A and B in vitro and on monoamine disposition in vivo
    Eric Southam
    Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park North, Harlow, Essex, CM19 5AW, UK
    Eur J Pharmacol 519:237-45. 2005
    ..Thus, altered monoamine metabolism in vivo is unlikely to account for the antidepressant action of the drug in bipolar depression...
  4. doi request reprint In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics
    Lee A Dawson
    Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Harlow, Essex, UK
    Eur J Pharmacol 627:106-14. 2010
    ..Taken together, these in vitro and in vivo characterisations of the tachykinin NK(3) receptor antagonists GSK172981 and GSK256471 support their potential utility in the treatment of schizophrenia...
  5. ncbi request reprint GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models
    Andrew D Medhurst
    Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline, Third Ave, Harlow, Essex, CM19 5AW, UK
    J Pharmacol Exp Ther 321:1032-45. 2007
    ..3 and 1 mg/kg p.o.), and attentional set shift (1 mg/kg p.o.). These data suggest that GSK189254 may have therapeutic potential for the symptomatic treatment of dementia in Alzheimer's disease and other cognitive disorders...
  6. ncbi request reprint Reversal of isolation-rearing-induced PPI deficits by an alpha7 nicotinic receptor agonist
    Jackie Cilia
    Psychiatry CEDD, GlaxoSmithKline, Third Avenue, Harlow, CM19 5AW, UK
    Psychopharmacology (Berl) 182:214-9. 2005
    ..Prepulse inhibition (PPI) deficits exhibited by isolation-reared rats are thought to model the sensorimotor gating deficits seen in schizophrenia...
  7. ncbi request reprint Anticonvulsant mechanisms for today and tomorrow
    Eric Southam
    Psychiatry CEDD, GlaxoSmithKline, Harlow, Essex, UK
    Drug News Perspect 18:483-7. 2005
    ....
  8. ncbi request reprint In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia
    Lee A Dawson
    Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline, Essex, UK
    Neuropsychopharmacology 33:1642-52. 2008
    ....
  9. ncbi request reprint Broad spectrum anticonvulsant activity of BW534U87: possible role of an adenosine-dependent mechanism
    Eric Southam
    GlaxoSmithKline, New Frontiers Science Park, Essex CM195AW, Harlow, UK
    Pharmacol Biochem Behav 74:111-8. 2002
    ....
  10. doi request reprint Chandelier cartridges in the prefrontal cortex are reduced in isolation reared rats
    Claire Bloomfield
    Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK
    Synapse 62:628-31. 2008
    ..This mimics findings in the PFC of schizophrenic patients where GAT-1-positive cartridges are reduced by 40% and is the first study to demonstrate changes in chandelier cartridges in an animal model of schizophrenia...